LivaNova Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 2/6
LivaNova verzeichnete einen durchschnittlichen jährlichen Gewinnzuwachs von 31.8%, während die Gewinne der Branche Medical Equipment jährlich um gewachsen und zwar um 14.8%. Die Umsätze verzeichneten einen durchschnittlichen jährlichen Gewinnzuwachs von gewachsen von 8%. Die Eigenkapitalrendite von LivaNova beträgt 14.2% und die Nettomargen betragen 12.8%.
Wichtige Informationen
31.77%
Wachstumsrate der Gewinne
34.22%
EPS-Wachstumsrate
| Medical Equipment Wachstum der Industrie | 8.90% |
| Wachstumsrate der Einnahmen | 7.96% |
| Eigenkapitalrendite | 14.23% |
| Netto-Marge | 12.81% |
| Letzte Ertragsaktualisierung | 30 Jun 2026 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Narrative-Update • Aug 05
LIVN: Cardiopulmonary And Epilepsy Momentum Will Support Future Re Rating
The analyst fair value estimate for LivaNova has been raised by $5 to $100, reflecting updated assumptions on growth, profitability, and P/E multiples as analysts highlight solid Q2 execution, higher long-term guidance, and supportive trends in cardiopulmonary and epilepsy reimbursement. Analyst Commentary Recent Street research on LivaNova points to a generally constructive tone, with several bullish analysts raising price targets following the latest Q2 update and guidance changes.
Narrative-Update • Jul 16
LIVN: Sleep Apnea Data And Neurostimulation Niche Support Balanced Future Outlook
The analyst price target for LivaNova has been raised to $84.80 from $80.60. Analysts cite recent target increases across the Street and supportive views on the neurostimulation and OSA markets as key factors behind the updated assumptions.Narrative-Update • Jun 26
LIVN: OSA Trial Success And PolySync Adoption Will Support Re Rating
Analysts have lifted their fair value estimate for LivaNova from $86.00 to $95.00, citing recent price target increases and continued confidence in obstructive sleep apnea trends highlighted at the SLEEP APSS Meeting and in follow up research. Analyst Commentary Recent commentary on LivaNova points to a constructive tone from bullish analysts, who are refining their views after industry events focused on obstructive sleep apnea and related therapies.Analyseartikel • Jun 20
LivaNova (LIVN) Stock Could Be 2.6% Undervalued After Recent Share Price Gains
LivaNova (LIVN) is back on investors’ radar after recent share price moves aligned with solid reported figures, including revenue of $1,433.456 million and net income of $107.145 million, prompting a closer look at its valuation. See our latest analysis for LivaNova. LivaNova’s share price has climbed 6.6% over the past month and 26.23% over the past 90 days, while its 1 year total shareholder return of 72.49% contrasts with a 5 year total shareholder return that is slightly down. Recent...Narrative-Update • Jun 12
LIVN: Sleep Apnea Trial Progress And PMA Win Support Balanced 2026 Outlook
Analysts have nudged their price target on LivaNova higher by $3, reflecting updated assumptions around fair value, discount rate, and future P/E expectations. What's in the News The journal Annals of Internal Medicine published 12-month data from LivaNova's OSPREY randomized controlled trial, covering safety and efficacy of proximal hypoglossal nerve stimulation using the aura6000 System for moderate to severe obstructive sleep apnea, supporting clinically significant improvements in apnea metrics and patient-reported outcomes.Seeking Alpha • Jun 11
LivaNova: My Targets Hold, Maintaining My Rating For H2
Summary LivaNova remains a 'HOLD' with a maintained $68/share price target, reflecting cautious optimism amid recent outperformance. Recent double-digit AEPS and revenue growth are offset by margin compression, segment mix concerns, and a lack of dividend support. Valuation appears stretched above 15x P/E, with historical cycles of overvaluation and subsequent normalization limiting near-term upside. LIVN's risks include slowing neuromodulation growth, unproven new products, and reliance on currency effects rather than organic demand. Read the full article on Seeking AlphaNarrative-Update • May 29
LIVN: 2026 Outlook Balances Sleep Apnea Progress With Execution And Margin Risks
Analysts have nudged their price target on LivaNova up by $1 to reflect updated assumptions around slightly higher revenue growth, a wider profit margin and a lower future P/E multiple, supported in part by recent Street research, including the $3 price target increase at Barclays. Analyst Commentary Bullish Takeaways Bullish analysts see the recent price target increase as consistent with expectations for steadier revenue contribution from LivaNova's existing portfolio, which they view as reasonably aligned with the updated assumptions on growth.Narrative-Update • May 05
LIVN: 2026 Outlook And Core Franchises Will Support Constructive Repricing
The updated analyst price target for LivaNova edges slightly lower to about $79.18 from $79.91, even as analysts point to recent Q4 strength, better than expected neuromodulation and cardiopulmonary results, and a solid 2026 outlook as support for their models. Analyst Commentary Recent Street research reflects a generally positive tone on LivaNova, with several firms lifting their price targets following Q4 results and updated 2026 commentary.
Narrative-Update • Apr 20
LIVN: 2026 Core Execution And OSA Expansion Will Test Fair Value View
The analyst price target for LivaNova has been raised by a few dollars per share, with the higher range of $73 to $85 cited in connection with stronger recent results, a firmer 2026 outlook, and expectations for sustained contributions from neuromodulation and cardiopulmonary. Analyst Commentary Recent Street research on LivaNova clusters in a higher target range of about $73 to $85, with most analysts pointing to recent results, solid contributions from neuromodulation and cardiopulmonary, and management's 2026 outlook as key inputs to their updated models.Narrative-Update • Apr 06
LIVN: 2026 Execution In Core Segments Will Test Fair Value View
Analysts have increased the blended price target for LivaNova by several dollars into the low to mid $70s, reflecting Q4 outperformance, constructive 2026 commentary, and updated models that indicate solid contributions from both neuromodulation and cardiopulmonary segments. Analyst Commentary Recent Street commentary around LivaNova clusters around upward revisions to price targets, but the tone is not uniformly bullish.Narrative-Update • Mar 22
LIVN: 2026 Setup And Core Franchises Will Support Constructive Repricing
The updated analyst price target for LivaNova rises from about $73 to roughly $80, reflecting analysts' responses to recent Q4 results, revised models for 2026, and supportive commentary on the company's neuromodulation and cardiopulmonary performance. Analyst Commentary Recent research updates show a cluster of higher price targets for LivaNova, with analysts focusing on Q4 performance, expectations for 2026, and the contribution from neuromodulation and cardiopulmonary.Narrative-Update • Mar 08
LIVN: Fairly Valued As 2026 Outlook Offsets Multiple Compression Risk
The updated analyst price target for LivaNova moves from a fair value estimate of $56 to about $67. Analysts point to recent price target hikes across the Street that reference Q4 outperformance, solid 2026 commentary, and expectations for consistent organic growth as key supports for the revised view.Narrative-Update • Feb 22
LIVN: 2026 Organic Drivers And Medicare Shift Will Support Re Rating
Narrative Update on LivaNova LivaNova’s updated analyst price targets, rising by roughly $8 to $12 per share into the mid to high $60s and low $70s, reflect analysts’ use of higher target multiples in line with comparable MedTech names. They also indicate a view that organic growth will play a larger role in relative valuation from 2026 onward.Narrative-Update • Feb 08
LIVN: Higher 2026 Medtech Multiples And Reimbursement Shift Will Drive Re Rating
Narrative Update on LivaNova LivaNova's analyst price targets have shifted higher into a roughly mid US$60s to US$70 range. Analysts point to adjusted target multiples that align more closely with comparable MedTech names and updated views on organic growth and sector setup into 2026.Narrative-Update • Jan 25
LIVN: Improved Reimbursement And 2026 Reset Will Support Constructive Repricing
Narrative Update The analyst price target on LivaNova has been lifted from about US$69 to roughly US$73 as analysts factor in higher target multiples, in line with recent moves in comparable MedTech names and modestly more constructive views reflected in updated fair value, discount rate, revenue growth, profit margin and forward P/E assumptions. Analyst Commentary Recent research updates on LivaNova cluster around higher price targets and a reset in expectations for 2026, with most of the discussion focused on how the shares should trade relative to other MedTech names as fundamentals and valuation reconnect.Narrative-Update • Jan 09
LIVN: Higher Medtech Multiples And Reimbursement Changes Will Support Re Rating
The analyst fair value estimate for LivaNova has moved from US$80 to US$86, reflecting analysts' use of higher target P/E multiples in line with recent moves in comparable MedTech names and updated views on revenue growth and profit margins. Analyst Commentary Bullish analysts are lifting their targets for LivaNova, pointing to higher target P/E multiples that are more in line with comparable MedTech peers.Narrative-Update • Dec 26
LIVN: Higher Reimbursement Will Still Leave Shares Vulnerable To Multiple Compression
Analysts have modestly raised their price target on LivaNova to $56.00 per share. This reflects slightly stronger long term revenue growth and margin expectations, partially offset by a lower assumed future earnings multiple and a marginally higher discount rate.Narrative-Update • Dec 12
LIVN: Improved Reimbursement And Raised Guidance Will Support Measured 2025 Outlook
Analysts have modestly revised their price target for LivaNova to remain effectively unchanged at approximately 69 dollars per share. This reflects stable assumptions around revenue growth, profitability, and valuation multiples, despite only incremental tweaks to the discount rate and long term earnings expectations.Analyseartikel • Dec 07
Improved Revenues Required Before LivaNova PLC (NASDAQ:LIVN) Stock's 26% Jump Looks Justified
LivaNova PLC ( NASDAQ:LIVN ) shareholders would be excited to see that the share price has had a great month, posting a...Narrative-Update • Nov 28
LIVN: Reimbursement Rate Increases And Guidance Raise Will Support 2025 Momentum
Analysts have slightly raised their price target for LivaNova, increasing it from $69.00 to $69.10. This change reflects incremental improvements in profit margin and discount rate assumptions.Narrative-Update • Nov 14
LIVN: Upgraded 2025 Outlook Will Drive Confidence Amid Business Momentum
Narrative Update on LivaNova Analyst Price Target Analysts have raised their price target for LivaNova by $4, now valuing the company at $69.00. This update reflects revised models that take into account management’s updated 2025 outlook and improved revenue growth projections.Analyseartikel • Aug 17
Optimistic Investors Push LivaNova PLC (NASDAQ:LIVN) Shares Up 28% But Growth Is Lacking
LivaNova PLC ( NASDAQ:LIVN ) shareholders would be excited to see that the share price has had a great month, posting a...Narrative-Update • Aug 08
Aging Populations And China Expansion Will Drive Device Adoption
Despite consensus revenue growth forecasts increasing to 6.4% and future P/E declining to 26.83x, LivaNova’s analyst price target remained unchanged at $64.70. What's in the News LivaNova raised full-year 2025 revenue growth guidance to 8.0-9.0% (constant currency) and 9.0-10.0% (organic).Analyseartikel • Aug 03
LivaNova (NASDAQ:LIVN) Has A Pretty Healthy Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Jul 07
LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Amongst other things, we'll want to...Analyseartikel • Apr 11
With LivaNova PLC (NASDAQ:LIVN) It Looks Like You'll Get What You Pay For
LivaNova PLC's ( NASDAQ:LIVN ) price-to-earnings (or "P/E") ratio of 29.3x might make it look like a strong sell right...Analyseartikel • Mar 21
Should You Think About Buying LivaNova PLC (NASDAQ:LIVN) Now?
LivaNova PLC ( NASDAQ:LIVN ), is not the largest company out there, but it received a lot of attention from a...
Neues Narrative • Mar 11
Investment In Obstructive Sleep Apnea And DTD Therapies Will Strengthen Future Market Position
Strategic focus on obstructive sleep apnea and cardiopulmonary advancements is key for revenue growth and market expansion.Analyseartikel • Feb 28
LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
It's been a mediocre week for LivaNova PLC ( NASDAQ:LIVN ) shareholders, with the stock dropping 15% to US$40.93 in the...Analyseartikel • Feb 25
We Like These Underlying Return On Capital Trends At LivaNova (NASDAQ:LIVN)
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analyseartikel • Dec 28
LivaNova PLC's (NASDAQ:LIVN) Price Is Right But Growth Is Lacking
You may think that with a price-to-sales (or "P/S") ratio of 2x LivaNova PLC ( NASDAQ:LIVN ) is a stock worth checking...Analyseartikel • Nov 12
We Think LivaNova's (NASDAQ:LIVN) Profit Is Only A Baseline For What They Can Achieve
Even though LivaNova PLC ( NASDAQ:LIVN ) posted strong earnings, investors appeared to be underwhelmed. We did some...Analyseartikel • Nov 03
LivaNova PLC Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
A week ago, LivaNova PLC ( NASDAQ:LIVN ) came out with a strong set of third-quarter numbers that could potentially...Analyseartikel • Oct 31
LivaNova (NASDAQ:LIVN) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Seeking Alpha • Oct 18
LivaNova: Economics Should Start Making Sustained Improvements
Summary LivaNova's Essenz product drives revenue growth, with successful rollout and premium pricing boosting guidance despite tough comparisons into the end of the year. Neuromodulation revenues, particularly from epilepsy treatments, show consistent growth, with underpenetrated markets and strong economics supporting secular growth. Discontinuation of the ANTHEM trial and nearing end of the DTD trial is setting up margins for sustained improvements together with operating leverage on growth. Despite potential liabilities from an Italian lawsuit, valuation looks compelling based on implied value of the DTD option, where they will decide on commercialization next year. Even outside the DTD growth opportunity, recurring economics and medical device industry margins suggest sustained improvements in economics coming. Read the full article on Seeking AlphaAnalyseartikel • Oct 02
Are Investors Undervaluing LivaNova PLC (NASDAQ:LIVN) By 31%?
Key Insights The projected fair value for LivaNova is US$76.07 based on 2 Stage Free Cash Flow to Equity Current share...Analyseartikel • Aug 21
LivaNova PLC's (NASDAQ:LIVN) Prospects Need A Boost To Lift Shares
LivaNova PLC's ( NASDAQ:LIVN ) price-to-sales (or "P/S") ratio of 2.1x might make it look like a buy right now compared...Analyseartikel • Jul 30
LivaNova (NASDAQ:LIVN) Might Have The Makings Of A Multi-Bagger
There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...Analyseartikel • Jul 04
At US$52.79, Is It Time To Put LivaNova PLC (NASDAQ:LIVN) On Your Watch List?
LivaNova PLC ( NASDAQ:LIVN ), is not the largest company out there, but it saw significant share price movement during...Aufschlüsselung der Einnahmen und Ausgaben
Aufschlüsselung der Einnahmen und Ausgaben
Wie LivaNova Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Gewinn | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 26 | 1,472 | 189 | 584 | 203 |
| 31 Mar 26 | 1,433 | 107 | 563 | 194 |
| 31 Dec 25 | 1,388 | -242 | 549 | 182 |
| 30 Sep 25 | 1,349 | -217 | 544 | 171 |
| 30 Jun 25 | 1,309 | -211 | 525 | 171 |
| 31 Mar 25 | 1,275 | -222 | 508 | 172 |
| 31 Dec 24 | 1,253 | 63 | 509 | 181 |
| 30 Sep 24 | 1,242 | 24 | 503 | 180 |
| 30 Jun 24 | 1,210 | -17 | 519 | 178 |
| 31 Mar 24 | 1,185 | -32 | 524 | 184 |
| 31 Dec 23 | 1,154 | 18 | 503 | 194 |
| 30 Sep 23 | 1,118 | 3 | 499 | 212 |
| 30 Jun 23 | 1,085 | -97 | 479 | 201 |
| 31 Mar 23 | 1,045 | -82 | 470 | 184 |
| 31 Dec 22 | 1,022 | -86 | 469 | 156 |
| 30 Sep 22 | 1,017 | -93 | 474 | 146 |
| 30 Jun 22 | 1,018 | -29 | 468 | 152 |
| 31 Mar 22 | 1,028 | -102 | 475 | 171 |
| 31 Dec 21 | 1,035 | -136 | 472 | 183 |
| 30 Sep 21 | 1,035 | -414 | 462 | 191 |
| 30 Jun 21 | 1,022 | -385 | 457 | 197 |
| 31 Mar 21 | 939 | -417 | 442 | 169 |
| 31 Dec 20 | 934 | -347 | 447 | 153 |
| 30 Sep 20 | 952 | -208 | 462 | 147 |
| 30 Jun 20 | 981 | -161 | 481 | 146 |
| 31 Mar 20 | 1,076 | -102 | 501 | 155 |
| 31 Dec 19 | 1,084 | -158 | 528 | 147 |
| 30 Sep 19 | 1,094 | -222 | 495 | 162 |
| 30 Jun 19 | 1,097 | -260 | 489 | 159 |
| 31 Mar 19 | 1,107 | -211 | 484 | 159 |
| 31 Dec 18 | 1,107 | -178 | 465 | 146 |
| 30 Sep 18 | 1,088 | 0 | 444 | 135 |
| 30 Jun 18 | 1,068 | 33 | 424 | 121 |
| 31 Mar 18 | 1,036 | 59 | 397 | 115 |
| 31 Dec 17 | 1,012 | 54 | 380 | 110 |
| 30 Sep 17 | 795 | 121 | 292 | 66 |
| 30 Jun 17 | 840 | 92 | 303 | 69 |
| 31 Mar 17 | 905 | 55 | 329 | 71 |
| 31 Dec 16 | 965 | 2 | 355 | 82 |
| 31 Dec 15 | 545 | -22 | 221 | 63 |
| 18 Oct 15 | 295 | 14 | 136 | 44 |
Qualität der Erträge: LIVN hat einen großen einmalig Verlust von $380.4M verbucht, der sich auf die Finanzergebnisse der letzten 12 Monate bis zum 30th June, 2026 auswirkt.
Wachsende Gewinnspanne: LIVN in der Vergangenheit profitabel geworden.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: LIVN ist in den letzten 5 Jahren profitabel geworden und hat seinen Gewinn um 31.8% pro Jahr gesteigert.
Beschleunigtes Wachstum: LIVN ist im letzten Jahr profitabel geworden, so dass die Wachstumsrate der Gewinne nur schwer mit dem 5-Jahres-Durchschnitt verglichen werden kann.
Erträge im Vergleich zur Industrie: LIVN ist im letzten Jahr profitabel geworden, so dass es schwierig ist, das Gewinnwachstum des letzten Jahres mit dem der Branche Medical Equipment (13.6%) zu vergleichen.
Eigenkapitalrendite
Hohe Eigenkapitalrendite: LIVNDie Eigenkapitalrendite des Unternehmens (14.2%) wird als niedrig angesehen.
Kapitalrendite
Rendite auf das eingesetzte Kapital
Entdecken Sie starke Unternehmen, die in der Vergangenheit erfolgreich waren
Unternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/19 03:38 |
| Aktienkurs zum Tagesende | 2026/08/19 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
LivaNova PLC wird von 24 Analysten beobachtet. 10 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| David Rescott | Baird |
| Scott Bardo | Berenberg |
| Michele Baldelli | BNP Paribas |